Madryn Health Partners, managed by Madryn Asset Management, is a direct lending fund based in New York that focuses on the healthcare sector. Established in 2017, the fund targets investments in areas such as healthcare services and supplies, pharmaceuticals and biotechnology, as well as life sciences and oncology. Madryn Asset Management specializes in identifying unique and transformative products, technologies, and services within the healthcare industry, leveraging its extensive experience to create long-term value for its portfolio companies. The firm employs an independent research approach to uncover attractive economic opportunities that aim to deliver strong risk-adjusted returns for its investors.

Techstars Central LLC, founded in 2006 and based in Boulder, Colorado, operates as a startup accelerator and venture capital firm focused on supporting early-stage technology-oriented companies. It specializes in a mentorship-driven accelerator program, selecting ten startups each summer to participate in a three-month incubation period, offering funding of $120,000 in exchange for equity. Techstars invests primarily in sectors such as fintech, artificial intelligence, blockchain, augmented reality, and IoT, while avoiding investments in medical devices, healthcare technology, and local service-oriented businesses. In addition to its primary accelerator, Techstars has various specialized programs, including those focused on music, retail, mobility, and social impact, with global reach extending to regions such as Africa, Asia, and Latin America. The firm prefers taking minority stakes, typically between six and ten percent, without seeking board representation or investor rights. Techstars has built a robust network of entrepreneurs, mentors, and corporate partners to foster innovation and growth within its portfolio, which includes over 1,000 companies with a significant collective market capitalization.

5AM Ventures is a venture capital firm founded in 2002 and headquartered in San Francisco, California, with an additional office in Boston. The firm specializes in seed- and early-stage investments, focusing on companies within the life sciences, healthcare, and technology sectors. Its investment portfolio includes firms involved in biopharmaceuticals, medical technology, drug delivery technologies, and research instruments. 5AM Ventures is recognized for its commitment to fostering innovation in advanced life science technologies.

Andreessen Horowitz LLC, founded in 2009 by Marc Andreessen and Ben Horowitz, is a venture capital firm based in Menlo Park, California. The firm specializes in investing across various stages of company development, from seed and early-stage to growth and late-stage ventures. It primarily targets the technology sector, with a strong emphasis on software, cloud computing, and Internet infrastructure. The firm also explores opportunities in consumer and business Internet applications, mobile software, and data storage, as well as at the intersection of computer science and life sciences, particularly in areas like digital therapeutics and computational medicine. Andreessen Horowitz is known for its significant financial backing, with investments typically ranging from $50,000 to $50 million. The firm has established multiple funds, including early-stage funds that focus on a variety of sectors, while explicitly avoiding investments in clean energy, transportation, and certain life sciences domains.

Temasek Holdings is an investment company based in Singapore, founded in 1974, with a diverse portfolio valued at approximately S$242 billion. The firm invests across various sectors, including telecommunications, media and technology, financial services, transportation, consumer products, real estate, life sciences, agriculture, and energy. Temasek's investment strategy is guided by long-term trends, focusing on themes such as transforming economies, rising middle-income populations, and emerging champions. Its investment structure includes a mix of liquid assets, listed and unlisted holdings, and private equity, reflecting a commitment to being a significant shareholder in both local and international businesses. Temasek Capital Management, a subsidiary, specializes in private equity and mid-stage technology and life sciences investments, further enhancing Temasek's global investment footprint.

Casdin Capital, LLC is an investment firm specializing in the life sciences and healthcare sectors. Founded in 2012 by Eli Casdin, who serves as the Chief Investment Officer, the firm employs a fundamental research approach to manage a long-short equity fund. Casdin Capital invests across a spectrum of opportunities, ranging from early-stage to late-stage private investments. As of October 2020, the firm manages approximately $2.2 billion in assets.

Pfizer is one of the largest pharmaceutical companies in the world, founded in 1849 and headquartered in the United States. The company is dedicated to improving health and well-being by applying scientific advancements and global resources. Pfizer manufactures and sells a diverse range of healthcare products, primarily focusing on prescription drugs and vaccines, which account for the majority of its sales. Notable products include the pneumococcal vaccine Prevnar 13, the cancer treatment Ibrance, and the cardiovascular drug Eliquis. With annual sales nearing $50 billion, Pfizer has a strong international presence, with nearly half of its sales derived from global markets, particularly emerging economies. The firm is committed to providing access to safe, effective, and affordable medicines to enhance patient outcomes and address pressing healthcare challenges.

New Enterprise Associates, Inc. is a private equity and venture capital firm established in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investments across various stages of company development, including seed, start-up, early stage, and later stage, with a focus on sectors such as information technology, healthcare, and energy technology. NEA's investment strategy encompasses a wide range of industries, including consumer internet, software, biotechnology, medical devices, and alternative energy. With over $19 billion in cumulative committed capital, the firm has a notable track record, having participated in more than 210 portfolio company IPOs and over 360 acquisitions. NEA aims to invest between $0.05 million and $20 million, targeting both domestic and international markets, particularly in Asia and the Americas.

OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, managing approximately $5 billion in assets. The firm specializes in a range of investment strategies, including private equity, venture capital, and public equity, targeting companies across the healthcare spectrum—from startups to large multinational corporations. OrbiMed invests in various sectors within the healthcare industry, including pharmaceuticals, biotechnology, life sciences, medical devices, and health IT. The firm typically invests between $3 million and $150 million, often seeking majority stakes in its portfolio companies. With a global investment approach, OrbiMed operates from offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, West Kowloon, and Luxembourg, focusing on opportunities in North America, Europe, Asia, and Israel. Its investment strategies are underpinned by fundamental analysis, encompassing investments in public equity, fixed income, and alternative markets.

Samsara BioCapital LLC is a private equity firm established in 2016 and located in Palo Alto, California. The firm specializes in investing in biotechnology companies across the United States, providing capital and strategic support to help advance innovations in the life sciences sector. Samsara BioCapital aims to identify and cultivate promising biotechnological advancements that can transform healthcare and improve patient outcomes.

Novo Holdings, established in 1999, is the holding company of the Novo Group, primarily managing the investment assets of the Novo Nordisk Foundation. Based in Copenhagen, with additional offices in San Francisco and Boston, Novo Holdings focuses on two main investment categories: Life Science Investments, which encompasses funding life science companies at various stages of development, and Financial Investments, which entails managing a diversified portfolio of equity and fixed income securities. As a prominent life science investor, Novo Holdings aims to create long-term value while ensuring that the Foundation can distribute returns for scientific, social, and humanitarian purposes to enhance public health and welfare. The company has also developed initiatives such as Novo Seeds, which supports early-stage applied research in life sciences, and invests in later-stage life science companies through growth equity. Novo Holdings maintains a strategic influence over affiliated companies, aligning their operations with the values and objectives of the Novo Group.

SMBC Venture Capital Co., Ltd. is the private equity and venture capital division of Sumitomo Mitsui Banking Corporation, focusing on growth capital and buyout investments. Established in 2005 and headquartered in Tokyo, with an additional office in Osaka, the firm invests across various sectors, including information technology, life sciences, services, and manufacturing. By leveraging its parent company's extensive financial services background, SMBC Venture Capital aims to support the development of innovative companies and foster growth within diverse industries.

Versant Ventures is a prominent healthcare investment firm headquartered in California, specializing in medical devices, biotechnology, and pharmaceuticals. Established in 1999, the firm manages approximately $2.3 billion and invests across all stages of company development, with a strong focus on discovering and developing innovative therapeutics. Versant has a global presence with offices in Canada, the U.S., and Europe, and its team comprises professionals with extensive investment, operational, and scientific expertise, allowing for a proactive approach to building companies. Since its inception, Versant has successfully facilitated the growth of over 65 companies, leading to numerous acquisitions and public offerings.

Invus Financial Advisors, LLC is an employee-owned hedge fund sponsor based in New York, specializing in investments across various stages including special situations, venture capital, and growth equity. Founded in 2006, the firm manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong. Invus focuses on making minority investments and often acts as a lead investor or part of a consortium, emphasizing a flexible approach tailored to the unique needs of each company. The firm has a long-standing commitment to empowering owner-managers, aligning its incentives with those of its partners, and recognizing that meaningful business transformation requires time and resilience. With a history of reinvesting capital from European families since its inception, Invus demonstrates a dedication to fostering long-term relationships and navigating challenges in pursuit of extraordinary performance.

Goldman Sachs is a global investment banking, securities, and investment management firm headquartered in New York City. Established in 1869, it provides a wide range of financial services to corporations, financial institutions, governments, and high-net-worth individuals. The firm operates through several segments, including Investment Banking, which offers financial advisory services related to mergers and acquisitions, and underwriting services for public and private offerings. Its Institutional Client Services segment facilitates client transactions across various asset classes and provides services like securities lending. The Investing & Lending segment focuses on long-term loans and investments in debt and equity securities, while the Investment Management segment offers portfolio management and wealth advisory services. Additionally, Goldman Sachs engages in private equity investments across multiple sectors and geographies, reinforcing its position as a leading investor in both public and private markets.

Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. As the strategic investment arm of Alexandria Real Estate Equities, it focuses on providing capital to seed, early-stage, and growth-stage companies within the healthcare sector. The firm emphasizes investments in biopharma, diagnostics, life sciences, research tools, agrifoodtech, and agtech. Alexandria Venture Investments aims to support innovative entities developing breakthrough technologies and therapies, leveraging its extensive industry knowledge and relationships with leading investors. Its approach is characterized by a commitment to fostering innovation and entrepreneurship in the life sciences and technology sectors.

Thuja Capital Management B.V. is a Netherlands-based venture capital and private equity firm that focuses on early-stage investments in the healthcare and biotechnology sectors. Established in 2005 and located in Utrecht, the firm specializes in incubation and bridge financing, targeting seed and start-up companies rather than growth capital. Its investment interests include life sciences, biopharmaceuticals, therapeutics, digital health, nutraceuticals, medical devices, diagnostics, and platform technologies. Thuja Capital typically invests between €0.25 million and €2.5 million in equity, as well as between €0.50 million and €1 million in debt, while actively seeking roles as lead or co-investor. The firm has a strong preference for engaging in the governance of its portfolio companies by taking positions on their supervisory boards. Its geographic focus encompasses the Netherlands, Belgium, Luxembourg, Flanders, and broader Western Europe.

IMM Investment Corp. is a private equity and venture capital firm based in Seoul, South Korea, established in 1999. The firm specializes in mezzanine investments and focuses on sectors such as information technology, healthcare, biotechnology, and manufacturing. It engages in various investment activities including mergers and acquisitions, corporate restructuring, management buyouts, and cross-border investments. In its growth stage investments, IMM allocates resources to startups, expansion, and mezzanine financing, with a significant emphasis on information technology infrastructure and digital content. The firm also targets medium-sized companies and prefers an active management role in its investments. Additionally, IMM Investment undertakes secondary investments and co-invests in buyout transactions, aiming for strategic opportunities in diverse industries, including telecommunications, entertainment, and biotechnology.

5Y Capital is a private equity and venture capital firm based in Shanghai, China, specializing in seed, startup, early venture, and growth capital investments. Established in 1992, the firm focuses on a diverse range of sectors, including healthcare, technology, fintech, internet services, consumer services, media, and life sciences, among others. It aims to support entrepreneurs in building innovative companies, particularly in China and other emerging markets in Asia/Pacific. Managing approximately USD 5 billion in dual-currency funds, 5Y Capital attracts investments from global sources, including sovereign wealth funds and family offices. The firm typically makes initial investments exceeding USD 500,000 per portfolio company. 5Y Capital operates under the Morningside Group, which is committed to socially responsible investing, particularly in educational opportunities and scientific research.

BlackRock is a global investment management corporation headquartered in New York City, specializing in a diverse array of asset classes and investment strategies. The firm manages equity, fixed income, and balanced mutual funds, along with hedge funds and exchange-traded funds. BlackRock also provides investment advisory services and engages in private equity and venture capital through its subsidiaries, focusing on direct investments and fund of funds across various sectors, including natural resources. The firm caters to a wide range of clients, from large institutions to individual investors, aiming to help them achieve their financial goals. With a commitment to transparency and client service, BlackRock has become the largest asset manager in the world, overseeing trillions of dollars in assets. Its global presence is supported by offices in key financial hubs, allowing it to address the unique needs of clients across different regions.

Santé Ventures is a life sciences venture capital firm that invests exclusively in early-stage companies developing innovative new medical technologies or healthcare delivery models. The firm was founded in 2006 and has $281 million in capital under management in two funds.

Boehringer Ingelheim is a global pharmaceutical company based in Ingelheim am Rhein, Germany, with a focus on improving patient care through innovation. Established in 2010, the Boehringer Ingelheim Venture Fund specializes in early-stage investments in life sciences, biotechnology, and digital health. The fund targets groundbreaking therapeutics and novel technologies, emphasizing areas such as immuno-oncology, regenerative medicine, and disease-related biomarkers. It typically invests up to €15 million over the lifetime of a company, with a specific focus on North America and Europe/Israel. Boehringer Ingelheim's commitment to advancing biomedical research aims to enhance patient outcomes through pioneering science and the development of new therapeutic concepts.

Polaris Partners is a venture capital firm founded in 1996 and headquartered in Boston, Massachusetts. With a focus on technology and healthcare sectors, Polaris invests in companies at all stages of development, from inception to profitable growth. The firm has a history of partnering with experienced entrepreneurs and innovators, aiming to enhance the way people live and work. In addition to its Boston headquarters, Polaris has offices in San Francisco and New York, and it actively targets investments in life sciences, biotechnology, and software industries across the United States and Europe. Over its more than two-decade history, Polaris Partners has established itself as a multibillion-dollar investment firm committed to fostering innovation and entrepreneurship.

NTT DoCoMo, Inc. is a prominent telecommunications company based in Tokyo, Japan, specializing in mobile services both domestically and internationally. The company operates through three main segments: Telecommunications Business, Smart Life Business, and Other Businesses. It offers a wide range of products and services, including smartphones, tablets, and various mobile plans, alongside value-added services such as VoLTE, LTE, and optical internet services. Additionally, NTT DoCoMo provides public wireless LAN, international roaming, and satellite communications. The firm also engages in diverse sectors such as finance, e-commerce, healthcare, and media, offering services like mobile payment solutions, educational content, and lifestyle guidance. Its venture capital arm, NTT Docomo Ventures, focuses on investing in technology startups across various fields including fintech and information technology. Established in 1991, NTT DoCoMo continues to innovate and expand its offerings under the auspices of its parent company, Nippon Telegraph and Telephone Corporation.

Nextech Invest is a venture capital and private equity firm based in Zurich, Switzerland, with a focus on early, mid-stage, and late-stage investments in healthcare and life sciences. Founded in 1998, the firm specializes in oncology, targeting companies that develop cancer drugs and diagnostics. It invests in projects that have demonstrated efficacy in preclinical animal models or possess viable device prototypes. Nextech Invest is particularly interested in interdisciplinary technical and scientific initiatives, including therapies, diagnostics, and medical technologies. The firm typically invests between CHF 1 million and CHF 5 million per financing round and aims for a board position in its portfolio companies. It seeks to exit investments within three years, primarily through trade sales. Nextech Invest considers opportunities globally, with a specific interest in companies based in Africa, the Middle East, Asia, North America, and Europe, including Switzerland and Germany.

Canaan VII is an early-stage venture capital fund managed by Canaan Partners, a global firm established in 1987 and based in San Francisco, California. The fund focuses on investing in the software and technology, media, and telecommunications (TMT) sectors within the United States. Canaan Partners manages a diverse portfolio with over 190 exits and has invested in more than 250 companies across various industries, including fintech, healthcare, and digital health. The firm employs a team of experienced investment professionals who seek to support visionary entrepreneurs with innovative ideas, providing capital ranging from $1 million to $20 million across different stages of development. With approximately $5 billion under management across multiple funds, Canaan Partners continues to play a significant role in fostering growth within the technology and healthcare landscapes.

Spring Lane Capital is a private equity firm based in Boston, Massachusetts, specializing in growth investments across North America. The firm employs an Integrated Deployment Capital model, which enables partnerships with entrepreneurs in the energy, water, food, and waste sectors. By focusing on smaller-scale projects and equipment, Spring Lane Capital aims to facilitate faster growth for companies that prioritize delivering effective solutions. Its investment strategy emphasizes impact in the transportation, agriculture, food products, and energy sectors, reflecting a commitment to sustainable development and addressing critical environmental challenges.

Foresite Capital is a multi-stage investment firm specializing in healthcare and life sciences, managing approximately $2 billion in assets. The firm employs a rigorous, data-driven approach to investment analysis and collaborates closely with its portfolio companies, offering a diverse team of scientists, engineers, analysts, and clinicians. This collaborative model enables Foresite Capital to understand the distinct business models within the healthcare sector. The firm focuses on addressing significant unmet clinical needs by investing in promising healthcare and life sciences enterprises across various stages of development. Additionally, Foresite Capital prioritizes companies that leverage data science and machine intelligence to innovate within the healthcare landscape. The firm is headquartered in San Francisco, with an additional office in New York.

Morgan Stanley is a multinational financial services firm that provides a wide range of services to corporations, governments, financial institutions, and individuals across various regions, including Europe, the Middle East, Africa, the Americas, and Asia. The firm is involved in capital raising, financial advisory services, corporate lending, and investment activities, offering underwriting for debt and equity securities, as well as advice on mergers, acquisitions, and restructurings. Additionally, Morgan Stanley operates several private equity and venture capital subsidiaries, focusing on middle-market investments in sectors such as energy, technology, healthcare, and infrastructure. These subsidiaries engage in management buyouts, corporate carve-outs, and growth equity investments, aiming to enhance portfolio company value through operational improvements and strategic acquisitions. The firm also has a significant wealth management division, serving a diverse range of clients, from individual investors to large corporations. Established in 1986 and headquartered in New York, Morgan Stanley emphasizes active capital management across public and private markets to deliver results for its clients.

work with private equity and venture capital fund managers, investment advisors and business entities from around the world.

Invest AG is the private equity and venture capital arm of Raiffeisenlandesbank Oberösterreich Aktiengesellschaft, specializing in investments in small and medium-sized enterprises. Established in 1994 and headquartered in Linz, Austria, the firm manages a portfolio of approximately 180 million euros, focusing on expansion and growth financing, management buyouts, and other financial strategies, while avoiding investments in tourism and restructuring. It generally invests between 1.5 million and 15 million euros, seeking a stake of no more than 49 percent in the companies it supports. The firm operates primarily in southern Germany, Austria, and Switzerland, with a particular emphasis on the Upper Austrian region for young entrepreneurs. Invest AG has invested in over 140 companies across various sectors and aims to exit its investments through methods such as IPOs and trade sales. The firm prides itself on providing long-term stability and expertise to its partners, assisting them in operational, commercial, and strategic matters.

Boxer Capital LLC is a venture capital firm founded in 2005 and based in the United States. The firm specializes in investing in both early-stage and late-stage biotechnology companies, focusing on the entire drug development lifecycle, from preclinical discovery to clinical and commercial stages. Boxer Capital targets private and public companies within the biotechnology sector, providing capital to support their growth and development. It operates as a subsidiary of Tavistock Life Sciences, leveraging its resources and expertise to foster innovation in the biotechnology field.

TMT Ventures is a venture capital company based in Pakistan that funds technology, media, and technology startups.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a non-profit organization established in 1982 that focuses on fostering the development and adoption of new technologies in the region. For over 30 years, it has served as a key provider of seed-stage capital, investing more than $170 million in over 1,750 regional technology companies, many of which have achieved industry leadership. In addition to financial support, Ben Franklin promotes university and industry partnerships that facilitate the commercialization of scientific discoveries. The organization is dedicated to strengthening the entrepreneurial ecosystem in Southeastern Pennsylvania, thereby creating jobs and enhancing the technology community.

RA Capital Management, L.P. is a Boston-based venture capital firm focused on growth capital and early-stage investments in the healthcare and life sciences sectors. Established in 2001, the firm specializes in funding companies involved in drug development, medical devices, diagnostics, and biotechnology. It engages in a range of investment stages, from seed funding to later rounds and public offerings, often preferring to co-invest and take board positions. RA Capital targets companies that are innovating in areas such as prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The firm is staffed by professionals with backgrounds in biology, chemistry, and medicine, providing them with a deep understanding of the scientific and regulatory landscape. This expertise allows RA Capital to identify promising technologies and offer strategic guidance, including potential partnerships and insights into public market demands.

Khosla Ventures is a venture capital firm established in 2004 by Vinod Khosla, a co-founder of Sun Microsystems. Based in Menlo Park, California, the firm manages over $5 billion and primarily invests in early-stage technology companies throughout the United States. Khosla Ventures provides capital, strategic advice, and venture assistance to entrepreneurs focused on breakthrough innovations across various sectors, including consumer technology, enterprise solutions, health, education, agriculture, and sustainable energy. The firm has a particular interest in high-risk, high-reward opportunities, often acting as a sole investor in "science or innovation experiments." Investment sizes typically range from $100,000 to over $20 million, allowing Khosla Ventures to support both traditional ventures and unconventional projects.

Qiming Venture Partners is a prominent venture capital firm established in 2006 and headquartered in Shanghai, with additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early to growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology in China. Since its inception, Qiming has built a reputation as a leading investment firm in the region, managing multiple funds with over $1 billion in assets. The firm aims to support promising entrepreneurs and innovative businesses, contributing to the development of China's dynamic economic landscape.

GE Equity, a division of General Electric, focuses on maximizing returns on the company's investment capital through strategic equity investments. Established with a blend of extensive equity investing experience and the operational expertise of GE, the division primarily seeks minority ownership stakes in established companies that exhibit high growth potential. GE Equity emphasizes various investment strategies, including growth capital, buy-out co-investments, secondary direct purchases, recapitalizations, and limited partner investments. The division leverages GE's global reach and industry knowledge to identify and capitalize on promising investment opportunities across diverse sectors.

TMT Investments PLC invests in high-growth technology companies across a number of core specialist sectors and has a significant number of Silicon Valley investments in its portfolio. Founded in 2010, TMT has invested in over 45 companies to date and has latest announced net assets of US$82million. The Company’s objective is to generate an attractive rate of return for shareholders, predominantly through capital appreciation. The Company is traded on the AIM market of the London Stock Exchange. www.tmtinvestments.com.

Echo Health Ventures is a venture capital firm based in Seattle, with additional offices in Durham and Portland. The firm focuses on investing in and supporting the growth of innovative healthcare companies. As stage-agnostic investors, Echo Health Ventures employs a unique strategic approach that emphasizes building strong, collaborative relationships with portfolio companies, rather than solely providing financial capital. Their investment strategy encompasses a broad range of sectors within healthcare, including digital health, aiming to accelerate the development of transformative innovations to a national scale.

BB Biotech Ventures G.P. is a Zurich-based venture capital firm that specializes in early-stage investments within the healthcare sector, focusing particularly on biotechnology and pharmaceuticals. The firm targets companies engaged in the development and marketing of drugs, therapeutics, medical devices, and diagnostics. With a global investment approach, BB Biotech Ventures emphasizes opportunities in Europe and the United States, seeking to invest in clinical-stage development and companies with IP-protected technologies. Investment amounts typically range from $7 million to $15 million, with the aim of supporting 10 to 12 companies at a time. As a subsidiary of Bellevue Asset Management AG, BB Biotech Ventures is backed by a dedicated team of investment advisors and an extensive network of healthcare specialists, striving to create value and maximize returns for its investors.

Intel Corporation is a leading global designer and manufacturer of semiconductor technologies, focused on powering the cloud, smart devices, and connected technologies. Founded in 1968 and headquartered in Santa Clara, California, Intel operates through various segments including Data Center Group, Internet of Things Group, Mobileye, and Client Computing Group, among others. The company offers a range of products such as central processing units, chipsets, accelerators, and memory solutions, catering to original equipment manufacturers, original design manufacturers, and cloud service providers. Intel has been transitioning from a PC-centric to a data-centric business model, emphasizing advancements in performance, power, and connectivity across various workloads. With a strong commitment to innovation, Intel also invests through Intel Capital in startups that drive technologies in cloud infrastructure, artificial intelligence, and 5G, among others. The company’s collaborations with prominent organizations aim to develop privacy-preserving analytics and enhance computing capabilities. As one of the largest semiconductor manufacturers by revenue, Intel continues to shape the future of computing and communications.

Qatar Investment Authority (QIA) is the sovereign wealth fund of the Government of Qatar, founded in 2005 to diversify the nation’s economic portfolio beyond its substantial oil and gas revenues. Headquartered in Doha, with offices in Mumbai, New Delhi, New York, and Beijing, QIA engages in investments across various asset classes, including public equity, fixed income, private equity, real estate, and alternative assets. The organization focuses on long-term strategic investments in diverse sectors, with a particular emphasis on infrastructure in the United States and startups in France. QIA aims to strengthen Qatar’s economy by reducing reliance on energy sales and positioning the country as an international center for finance and investment management. It operates under strict financial and commercial disciplines, managing investments through its subsidiaries, including Qatar Holding LLC and Qatari Diar for real estate ventures.

Roche is a global healthcare company based in Basel, Switzerland, that specializes in pharmaceuticals and diagnostics. It focuses on improving patient outcomes through innovative medicines and diagnostic solutions. Roche's pharmaceutical division provides a wide range of treatments for various medical conditions, including oncology, virology, and inflammation, with well-known products such as Avastin, Herceptin, and MabThera. The diagnostics division offers comprehensive in-vitro diagnostic tests and systems, playing a crucial role in early disease detection, monitoring, and research. Roche Molecular Systems develops and commercializes diagnostic tests employing advanced PCR technologies for virology, blood screening, and oncology. Additionally, the Roche Venture Fund invests in early-stage life science companies, supporting innovations in biotechnology and diagnostics with a portfolio that spans multiple countries. Through these initiatives, Roche continues to enhance healthcare solutions worldwide while committing to significant investments in research and development.

Insight Partners is a global private equity and venture capital firm established in 1995, specializing in growth-stage investments in the software, internet, and data services sectors. Headquartered in New York City, with additional offices in London, Tel Aviv, and Palo Alto, the firm manages over $75 billion in assets and has invested in more than 750 companies worldwide. Insight Partners focuses on partnering with high-growth technology and software companies that are driving significant change in their industries. The firm aims to support visionary executives by providing practical, hands-on expertise throughout their growth journey, from initial investment to public offering. With a strong commitment to fostering a culture of growth and opportunity, Insight Partners has seen over 55 portfolio companies achieve IPO status.

Section 32 is a California-based venture capital firm founded in 2017 by Bill Maris, who previously served as the CEO of Google Ventures. The firm focuses on early-stage investments in the life sciences, healthcare, and technology sectors across the United States. With a preference for investing between $5 million and $10 million in 25 to 30 companies, Section 32 seeks to support innovative projects that have the potential to significantly enhance the human condition. The firm operates primarily from San Diego and has raised a total of $150 million for its investment activities, targeting advancements in areas such as artificial intelligence, cybersecurity, fintech, and biotechnology. Through its strategic investments, Section 32 aims to accelerate the discovery, development, and distribution of transformative technologies.

NVP Associates, LLC is a venture capital and private equity firm based in Palo Alto, California, specializing in a diverse range of investment stages and sectors. Established in 1961, the firm focuses on seed, startup, early, mid, and late-stage investments in both listed and unlisted companies, with particular emphasis on technology, healthcare, consumer products, and financial services. NVP Associates seeks to invest between $10 million and $150 million, depending on the stage and nature of the investment, often leading or co-investing with other firms. The firm has a global investment strategy, concentrating on markets in the Asia-Pacific region, the United States, India, Israel, and China. Its portfolio spans various industries, including medical devices, information technology, enterprise software, and digital health. NVP Associates aims to support companies with strong growth potential, leveraging its extensive network and operational expertise to foster development and achieve significant returns.

MUFG announced today the establishment of MUFG Innovation Partners Co., Ltd. (“MUIP”) that will manage corporate venture capital funds of MUFG to accelerate open innovation and strengthening partnerships with FinTech related startups.

Seventure Partners is a Paris-based venture capital firm founded in 1997, specializing in investments in life sciences and information and communication technology. With offices in Munich, Geneva, London, and Basel, the firm manages approximately €660 million and focuses on identifying and nurturing innovative companies with high growth potential across North America, Europe, Asia-Pacific, the Middle East, and Africa. Seventure Partners engages closely with entrepreneurs, leveraging its expertise and extensive networks to support the development of emerging European leaders in their respective fields. The firm employs a team of over 20 professionals, including 15 investors, who possess significant knowledge in technology and private equity operations. Seventure’s investment strategy encompasses various sectors, including TMT, industrial, healthcare devices, and supply, with a typical investment range of €0.5 million to €2 million over a six-year horizon.

TMI is a venture capital firm based in Taipei, Taiwan, founded in 2012. The firm specializes in incubation, startups, and early-stage investments, focusing primarily on mobile, internet, and e-commerce sectors. TMI also provides acceleration services for hardware companies. It typically invests between $50,000 and $300,000 in its portfolio companies, which are primarily located in Southeast Asia.